Quantcast

Pharma news

Foamix Pharma Releases positive phase 3 acne data; stock soars 50% in after hours

Foamix Pharmaceuticals showed its topline results of its third Phase 3 clinical trial (FX2017-22) of FMX101 for the treatment of moderate-to-severe acne.

Posted in Approval, news | Tagged , | Leave a comment

Karuna gets $42 million in financing round

PureTech Health and its affiliate Karuna have completed a $42 million Series A financing round, which will be used to

Posted in Approval, news | Tagged , | Leave a comment

Amryt’s Epidermolysis Bullosa treatment granted Rare Pediatric Disease from US FDA

Amryt ensure US Food and Drug Administration’s grant a Rare Pediatric Disease designation for its lead development asset AP101, for

Posted in Approval, news | Tagged , | Leave a comment

Sanofi net income €762M in second quarter

Sanofi reported €762m of net income in the second quarter 2018, after net sales of €8,176 million, down 5.7% on a

Posted in Approval, news | Tagged | Leave a comment

Single bacterial strains from the human gut microbiota can serve as HDAC inhibitors

4D pharma showed that specific single bacterial strains from the human gut microbiota can serve as therapeutic inhibitors of the

Posted in Approval, news | Tagged | Leave a comment

Beximco’s fifth ANDA approved in USA

Beximco Pharmaceuticals got approval from the US Food and Drug Administration (FDA), for its Nadolol tablets, a generic equivalent of Bristol-Myers Squibb’s

Posted in Approval, news | Tagged | Leave a comment

Apricus Biosciences merges with Seelos Therapeutics

Apricus Biosciences will merge with Seelos Therapeutics, Inc., a privately-held biotechnology company, in an all-stock transaction, it announced on Monday,

Posted in Approval, news | Tagged , | Leave a comment

Positive data supports product opportunities for XF-73 in dermal infection indications

Destiny Pharma’s first of two Phase 1 safety clinical studies of testing XF-73’s potential to cause dermal irritation, as Destiny’s

Posted in Approval, news | Tagged , | Leave a comment

Neurodegeneration may be tied to drainage issues in the brain

PureTech Health’s new internal programme focused on treating central nervous system (CNS) disorders via modulation of the brain’s lymphatic system,

Posted in Approval, news | Tagged , | Leave a comment

WuXi’s API production site in china passes USFDA’s inspection

WuXi STA Pharmaceutical’s Active Pharmaceutical Ingredient (API) production site in China, at Jinshan, Shanghai, has passed its fourth inspection from

Posted in Approval, news | Tagged | Leave a comment